Evaluation of the in vitro and in vivo angiogenic effects of exendin-4

Biochemical and Biophysical Research Communications

Volumn 434, Issue 1, 2013, Pages 150-154

  Kang, Hye Min ^a   Kang, Yujung ^b   Chun, Hyung J ^b   Jeong, Joo Won ^a   Park, Chan ^a  

^a Kyung Hee University Hospital   (South Korea)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Endothelial cell; Exendin 4; GLP 1 receptor; Glucagon like peptide (GLP) 1

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MATRIGEL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPROUTING; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; AORTA; CELL MOVEMENT; GLUCAGON-LIKE PEPTIDE 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; VENOMS;

EID: 84876787394     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.053     Document Type: Article

References (14)

1. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992, 267:10931-10934.
2. Carmeliet P., Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann. NY Acad. Sci. 2000, 902:249-262.
3. Ahren B., Larsson H., Holst J.J. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1997, 82:473-478.
4. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
5. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992, 267:7402-7405.
6. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 1993, 268:19650-19655.
7. Serre V., Dolci W., Schaerer E., Scrocchi L., Drucker D., Efrat S., Thorens B. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence. Endocrinology 1998, 139:4448-4454.
8. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
9. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E1209-1215.
10. Erdogdu O., Nathanson D., Sjoholm A., Nystrom T., Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol. Cell. Endocrinol. 2010, 325:26-35.
11. Nakatsu M.N., Davis J., Hughes C.C. Optimized fibrin gel bead assay for the study of angiogenesis. J. Vis. Exp. 2007, 12:186.
12. Best J.H., Hoogwerf B.J., Herman W.H., Pelletier E.M., Smith D.B., Wenten M., Hussein M.A. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011, 34:90-95.
13. Xiao-Yun X., Zhao-Hui M., Ke C., Hong-Hui H., Yan-Hong X. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med. Sci. Monit. 2011, 17:BR35-BR41.
14. Takasawa W., Ohnuma K., Hatano R., Endo Y., Dang N.H., Morimoto C. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem. Biophys. Res. Commun. 2010, 401:7-12.